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Abstract
Background: Women with history of gestational diabetes mellitus (GDM) are at higher risk of developing type 2
diabetes within 5 years after delivery. Evidence that lactation duration influences incident type 2 diabetes after
GDM pregnancy is based on one retrospective study reporting a null association. The Study of Women, Infant
Feeding and Type 2 Diabetes after GDM pregnancy (SWIFT) is a prospective cohort study of postpartum women
with recent GDM within the Kaiser Permanente Northern California (KPNC) integrated health care system. The
primary goal of SWIFT is to assess whether prolonged, intensive lactation as compared to formula feeding reduces
the 2-year incidence of type 2 diabetes mellitus among women with GDM. The study also examines whether
lactation intensity and duration have persistent favorable effects on blood glucose, insulin resistance, and adiposity
during the 2-year postpartum period. This report describes the design and methods implemented for this study to
obtain the clinical, biochemical, anthropometric, and behavioral measurements during the recruitment and follow-
up phases.
Methods: SWIFT is a prospective, observational cohort study enrolling and following over 1, 000 postpartum
women diagnosed with GDM during pregnancy within KPNC. The study enrolled women at 6-9 weeks postpartum
(baseline) who had been diagnosed by standard GDM criteria, aged 20-45 years, delivered a singleton, term
(greater than or equal to 35 weeks gestation) live birth, were not using medications affecting glucose tolerance,
and not planning another pregnancy or moving out of the area within the next 2 years. Participants who are free
of type 2 diabetes and other serious medical conditions at baseline are screened for type 2 diabetes annually
within the first 2 years after delivery. Recruitment began in September 2008 and ends in December 2011. Data are
being collected through pregnancy and early postpartum telephone interviews, self-administered monthly mailed
questionnaires (3-11 months postpartum), a telephone interview at 6 months, and annual in-person examinations
at which a 75 g 2-hour OGTT is conducted, anthropometric measurements are obtained, and self- and interviewer-
administered questionnaires are completed.
Discussion: This is the first, large prospective, community-based study involving a racially and ethnically diverse
cohort of women with recent GDM that rigorously assesses lactation intensity and duration and examines their
relationship to incident type 2 diabetes while accounting for numerous potential confounders not assessed
previously.
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Approximately 7% of all pregnant women are diagnosed
with gestational diabetes mellitus (GDM) and comprise
a high-risk group for future development of type 2 dia-
betes mellitus. Women with GDM are 7 times more
likely to develop type 2 diabetes after pregnancy [1],
although a 4-fold higher incidence of overt diabetes
after GDM pregnancy was reported by Gunderson et al.
after excluding women with hyperglycemia before preg-
nancy based on prepregnancy blood glucose measures
[2].
About 5-10% of women will be diagnosed with type 2
diabetes within the first 6 months after GDM pregnancy
and another 10-15% will develop diabetes within the
subsequent 1-2 years postpartum [3-6]. Predictors of
diabetes among women with a history of GDM include
maternal antepartum and early postpartum glycemia,
insulin use during pregnancy, pancreatic b-cell compen-
sation for higher insulin resistance and GDM recurrence
[6] and family history of diabetes, especially having a
mother with diabetes [7,8]. Prepregnancy obesity, gesta-
tional weight gain, postpartum weight gain, and subse-
quent pregnancies have been associated with higher risk
of diabetes years later [6,7,9-15]. In cross-sectional stu-
dies, greater central obesity has been reported in women
who developed type 2 diabetes after GDM pregnancy
[11,12,16].
Lactation intensity and duration have rarely been
assessed in relation to type 2 diabetes after GDM preg-
nancy. Of 28 studies cited in a comprehensive review by
Kim et al.[6] and 5 subsequent studies [9,12,13,17,18],
only 5 of 33 studies examined lactation status (yes or
no) in relation to incident diabetes, and the findings
were inconclusive [16,18-21]. Most studies examined
“any” lactation versus none, have utilized primarily ret-
rospective designs, involved Latinas, did not conduct
standardized postpartum screening for diabetes, and had
relatively small sample sizes. Of the only two prospec-
tive studies that examined lactation duration in relation
to incident diabetes, a previous history of GDM was not
ascertained [18,22]. These two studies, including either
white or Chinese women, reported that increasing lacta-
tion duration was associated with lower incidence of
diabetes after pregnancy, which was ascertained via self-
report in mid to late life. A retrospective cohort study
of White women with a history of GDM found a null
association between lactation duration and incident dia-
betes ascertained by self-report [18]. A major limitation
of these three previous studies is that they did not con-
duct periodic standardized screening of women to ascer-
tain diabetes incidence after pregnancy.
One of the few prospective studies to examine women
of reproductive age (50% Black and 50% White) during
a 20 year period (1985-2005) is the U.S. multi-center
study, the Coronary Artery Risk Development in Young
Adults (CARDIA) Study. In CARDIA women, glycemia
was measured both before pregnancy and post-weaning
to assess the association between lactation duration and
incidence of the metabolic syndrome in women with
and without previous GDM pregnancies. Longer dura-
tion of lactation was associated with a 50-89% reduction
in incident metabolic syndrome on average 8 years after
pregnancy among women with a history of GDM as
well as those with no history of GDM [23]. To our
knowledge, lactation intensity has not been evaluated in
any previous studies that examined incident diabetes
after GDM pregnancy.
We herein critically review the epidemiologic evidence
and biological plausibility that lactation may protect
women from developing type 2 diabetes in mid to late
life. We examine findings from studies of lactation and
persistent changes in biochemical risk factors, as well as
incident metabolic disease, including type 2 diabetes,
after pregnancy. The evidence for short-term changes in
metabolic risk profiles and limited evidence from large
epidemiologic studies were the impetus for the funding
and design of the SWIFT study of postpartum women
with recent GDM pregnancy.
The goal of the SWIFT study is to prospectively
examine lactation intensity and duration in relation to
incident diabetes after GDM pregnancy. The SWIFT
study specific aims, design, and methodologies are pre-
sented as well as a description of the participant eligibil-
ity criteria. We also summarize the recruitment, in-
person study assessments and retention protocols for
SWIFT, a prospective postpartum cohort of women
with recent GDM who delivered a term infant within
the Kaiser Permanente Northern California (KPNC)
integrated healthcare system.
Physiological effects of lactation on metabolic status:
biological plausibility
Lactation has favorable effects on maternal metabolism
including increased glucose-disposal rates, enhanced
lipolysis and diverting glucose (> 50 g/d) for utilization
in milk production [24-26]. Data are less available
regarding whether lactation protects b-cell function
[27,28], or has lasting effects on maternal glucose toler-
ance to ultimately influence the risk of diabetes after
GDM pregnancy. Prospective studies are needed that
assess lactation more precisely and completely in rela-
tion to changes in oral glucose tolerance and body adip-
osity to determine conclusively whether lactation may
delay or prevent future diabetes.
Lactation and glucose homeostasis
Overall, alterations in the hormonal milieu and respon-
siveness during lactation are designed to favor lower
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the mammary gland [25] and increased lipolysis to
accommodate the metabolic demands of milk produc-
tion. Lactation is characterized by increased maternal
basal metabolic rates, greater energy needs for milk pro-
duction, and mobilization of fat stores [25,29,30]. Lactat-
ing women generally exhibit lower blood glucose and
insulin concentrations and higher glucose production
rates due to increased glycogenolysis (not gluconeogen-
esis or increased use of free fatty acids) [31]. In other
cross-sectional studies, lactating women had lower fast-
ing plasma glucose and insulin levels [32], and lower
post-absorptive insulin levels than non-lactating women
[26].
Frequently sampled oral glucose tolerance (FSOGT)
tests showed a higher corrected insulin response at 30
min (p < 0.03) in non-lactating (1.24 + 0.26 μU· mg-2
·102) than lactating women (0.67 + 0.11 μU· mg-2 ·102).
Thus, basal and glucose-stimulated b-cell secretory
activity for a standardized glucose load may be lower for
lactating than non-lactating women [27], indicating that
lactation may reduce the load on the b-cells as reported
in studies that examined women without glucose toler-
ance during pregnancy as outlined above.
Lactation’s effects on maternal body weight
About 4-6 kg of body fat is stored during pregnancy
partially in preparation for fetal growth during late
gestation and lactation [33,34]. In small clinical studies,
average weight loss during the first 6 months of lacta-
tion in affluent populations is about -0.5 to -0.8 kg/
month [35]. Although lactation increases total energy
expenditure by 15-25% for milk production [25,36], evi-
dence is inconsistent as to whether lactation promotes
greater postpartum weight loss [37].
Prospective studies that measured maternal weights
before or during early pregnancy reported lower post-
partum weight retention, more rapid return to prepreg-
nancy weight or greater weight losses within 6 months
to 1 year postpartum among lactating women
[30,38-41]. Greater frequency of lactation and higher
breast milk energy output are associated with greater
weight loss from 3 to 6 months. Higher intensity of
breastfeeding from 2.5 to 6 months postpartum [39,42]
and for the first year [43] resulted in 2 kg greater aver-
age maternal weight loss. Another study among women
(n = 110) classified as fully breastfeeding, partly breast-
feeding, or bottle-feeding at six different points in time
found that women who lactated more than 1 year lost 2
kg more by 18 months postpartum than women who
bottle-fed [43]. Olson et al. in 2003 [38] reported 1.2 kg
lower postpartum weight retention in women still
breastfeeding at 1 year postpartum, after controlling for
first trimester weight and other confounders. More
recently, an analysis with a large sample of mothers (n =
32, 920) enrolled in the Special Supplemental Nutrition
Program for Women, Infants and Children (WIC)
resulted on a modest but significant effect of lactation
on weight retention from one pregnancy to the next
[44]. Thus, after adjusting for potential confounder
effects, lactation for 20 or more weeks resulted on 0.39
kg less weight retention at the beginning of the second
pregnancy compared to no lactation. Studies that care-
fully assessed lactation exposure demonstrate that
greater intensity and duration of lactation promote
greater postpartum weight loss.
Overall and regional adiposity during lactation
During lactation, fat stores are mobilized to a greater
extent from the trunk and thighs [45-48]. Lactating
women show greater declines in suprailiac and subscap-
ular regions but fat increased in the triceps region
[35,49]. However, skinfold thickness is a relatively
imprecise measure for evaluating total body fat or regio-
nal fat, and does not precisely assess changes due to
fluid losses [30,41,47].
In studies using dual-energy X-ray absorptiometry
(DXA) to measure changes in body composition and
regional fat distribution in lactating and non-lactating
women, total fat mass showed a greater linear 12-month
decline in lactating women versus non-lactating women
with the largest decline between 3 and 6 months [35].
No differences in fat mobilization from leg, arm and
trunk regions were found, but lactating women had a
non-significant 2 kg greater decline in total fat mass
[35]. However, this study lacked statistical power to
detect this clinically significant difference. Central adip-
osity is of greater importance metabolically than overall
obesity since intra-abdominal (visceral) fat is associated
with development of obesity-related insulin resistance
and progression to type 2 diabetes [50]. Visceral fat is
more metabolically active and is thought to differ from
sub-cutaneous fat in the production of adipocytokines
that may regulate insulin sensitivity [51].
Figure 1 presents our theoretical model and sum-
marizes the hypothesized relationships of lactation to
immediate and long-term effects on glucose tolerance as
discussed in the preceding sections.
Lactation and postpartum metabolic status in women
with a history of GDM
McManus et al. administered a frequently sampled
intravenous glucose tolerance test (FSIGT) to 14 lactat-
ing and 12 non-lactating women with previous GDM at
3 months postpartum, who were matched for age,
weight, postpartum weight loss and exercise habits. In
lactating women, insulin sensitivity, glucose effectiveness
and first phase insulin response to glucose (AIRg)
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statistical significance was not reached given the small
sample size. However, the disposition index (DI = insu-
lin sensitivity multiplied by AIRg) was 2.5 times higher
(129.9 ± 26.0 vs 53.4 ± 18.0 × 10(-4) min(-1); p < 0.05)
in lactating versus non-lactating women [28]. The
higher DI supports the hypothesis that lactation pro-
motes much better b-cell compensation for insulin resis-
tance, which may help maintain b-cell function in the
long-term. Because glucose is diverted for milk produc-
tion, reduced plasma glucose levels “unload” the b-cells
such that b-cell function is preserved; insulin response
for given levels of resistance is improved. These physio-
logic changes may sustain glucose tolerance and protect
against b-cell exhaustion leading to type 2 diabetes.
Lactation is associated with more favorable glucose
metabolism at 2-3 months postpartum in some, but not
all small clinical studies. Fasting plasma glucose and
insulin levels and incremental responses of plasma glu-
cose (at 30, 60, 90 and 120 min) to a test meal did not
differ between lactating (n = 12) and non-lactating (n =
7) groups, but lactating women had lower plasma insu-
lin response and higher rates of glucose utilization [52].
No significant differences in plasma glucose and insulin
levels after a 50-gram OGTT were found between lac-
tating and non-lactating groups in two other studies
[27,32]. However, the b-cell secretory response assessed
by the corrected insulin response at 30 min (CIR 30
min) during the OGTT was reduced by half for lactating
versus non-lactating women [0.67 ± 0.11 vs. 1.24 ± 0.26
μU· mg-2 ·102] [27].
A series of cross-sectional and follow-up studies of
Latinas with previous GDM examined early postpartum
lactation with conflicting findings. Lactation was asso-
ciated with lower prevalence of diabetes and better glu-
cose tolerance at 4-12 weeks postpartum; a lower total
area under the glucose tolerance curve (AUC) (17.0 ±
4.2 vs. 17.9 ± 5.0 g.minute/dL), and lower fasting serum
glucose (93 ± 13 vs. 98 ± 17 mg/dL) and 2-hour OGTT
glucose levels (124 ± 41 vs. 134 ± 49 mg/dL) after con-
trolling for body mass index (BMI), maternal age and
insulin use during pregnancy [19]. Lactation status at 4-
16 weeks postpartum was not associated with risk of
type 2 diabetes within 5 years [20]. Buchanan et al.
examined 122 Latinas with normal fasting glucose and
no insulin use during GDM pregnancy and found that
those diagnosed with diabetes within 6 months postpar-
t u mw e r el e s sl i k e l yt oh a v eb r e a s t f e d( 4 2 % )t h a nt h o s e
with normal glucose tolerance (71%) [16]. Finally,
among 91 Latinas receiving OGTT screening at 15-
month intervals, lactation status (yes vs. no) at 11-26
months postpartum did not influence onset of type 2
diabetes [21]. Other confounders such as employment,
intentional dieting, dietary intake, and physical activity
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Figure 1 Theoretical model of effects of lactation on glucose tolerance and Type 2 DM.
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gain and higher BMI during young adulthood are asso-
ciated with insulin resistance and greater risk of type 2
diabetes [53-55]. No studies have examined changes in
waist girth or central adiposity after GDM pregnancy.
Inconclusive evidence for lasting effects on future disease
Clinical and epidemiologic evidence support the hypoth-
esis that lactation has immediate favorable effects on
maternal glucose tolerance, and may reduce the load on
the b-cells by lowering plasma glucose levels through
diversion of glucose for milk production, thereby lessen-
ing insulin demands. The Nurses Health Study (NHS)
found a lower incidence of self-reported diabetes by 14-
15% for each year of lactation, and a stronger risk
reduction for exclusive lactation. This association was
independent of current BMI and behavioral risk factors,
and there was no interaction by parity. However, the
association was null among women with history of
GDM, in whom lactation and other lifestyle behaviors (i.
e., diet or exercise) were unrelated to diabetes risk [18].
By contrast, a subsequent 20-year longitudinal study
based on biochemical measurements before pregnancy
and after weaning, found that lactation for 2 or more
months versus less than 1 month was associated with 2
to 8-fold lower incidence of the metabolic syndrome
after GDM pregnancy controlling for pre-pregnancy
risk, socio-demographics, behavioral changes, and race
[23].
Evidence is equivocal that lactation, except for exclu-
sive lactation for several months, promotes greater
weight loss during the first year postpartum. Few studies
have included diverse racial and ethnic groups, assessed
postpartum behaviors, weight loss, regional adiposity, or
other factors in relation to long-term maternal glucose
tolerance after GDM pregnancy.
Lactation has immediate favorable effects on glucose
tolerance, but only limited evidence for any long-term
effects. Studies have never prospectively assessed both
intensity and duration of lactation as well as other
major confounders in women with recent GDM. Well-
controlled, prospective studies with more precise and
complete measures of lactation are required to assess
the impact on development of type 2 diabetes. Data are
currently unavailable to conclude that lactation reduces
the risk of type 2 diabetes after GDM pregnancy.
The Diabetes Prevention Program (DPP) showed a
greater than 50% reduction in the incidence of diabetes
with a weight management/exercise program for high
risk adults, demonstrating that a relatively modest
weight loss of 3-4 kg (equivalent to 5% of initial body
weight) could prevent diabetes [56]. A relatively modest
2 kg higher weight loss within 1 year has been attributed
to intensive lactation in the studies that prospectively
assessed lactation intensity and measured body weights.
Based on the DPP findings, lactation may lower the inci-
dence of diabetes by 30% after GDM pregnancy based
on loss of fat mass. If lactation exerts other effects (e.g.,
preservation of b-cell function) that are independent of
adiposity, then the reduction in type 2 diabetes may be
even greater.
The American Academy of Pediatrics recommends
breastfeeding as the preferred method of infant feeding
for at least 1 year of age [57]. Although 80% of U.S.
women initiate lactation, only 45% report “any” level of
breastfeeding at 6 months [57]. Lactation is a modifiable
behavior that may be translated into a practical, low-
cost intervention, and has the potential to enhance post-
partum interventions that have primarily relied on stra-
tegies to promote healthy diet and increase physical
activity levels. Breastfeeding may prevent recurrence of
GDM in a future pregnancy, and thereby also influence
the risk of type 2 diabetes in the offspring [58-61].
The SWIFT study design and aims: prospective GDM
cohort
The overall objective of this study is to assess whether
lactation prevents the onset of type 2 diabetes during
the first 2 years postpartum among women with recent
GDM, after taking into account their age, race/ethnicity,
parity, weight status, education, severity of gestational
glucose intolerance, GDM recurrence history, family his-
tory of diabetes, clinical or medical risk factors, and
other postpartum behaviors.
Specifically, we aim to determine whether intensive
lactation compared with intensive formula feeding is
associated with:
Lower 2-year incidence of type 2 DM (Aim 1);
Lower fasting and 2-hour post-load plasma glucose
levels, and lower insulin resistance (Aim 2); and
Lower total and central adiposity, and higher plasma
adiponectin levels (Aim 3).
Another objective of the study is to determine
whether lower adiposity is associated with lower inci-
dence of type 2 diabetes in this population (Aim 4).
Materials and methods
Study design and setting
The study population is recruited from members of the
KPNC integrated healthcare system who received prena-
tal care and delivered at a KPNC hospital. The demo-
graphic profile of KPNC membership is representative
of the diverse racial and ethnic groups in the same geo-
graphical area [62].
The study design is a prospective cohort of women
who were diagnosed with GDM before 34 weeks gesta-
tion. During the study period, GDM diagnosis is based
on standardized 3-hour 100 g oral glucose tolerance
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criteria [63] as recommended by the American Diabetes
Association (ADA) [64]. Two or more of the four
plasma glucose values have to meet or exceed the
plasma glucose thresholds recommended by the ADA
[64] and the American College of Obstetricians and
Gynecologists (ACOG) [65], and received standard treat-
ment for GDM within by KPNC prenatal care providers.
Standard obstetrical practice at KPNC involves post-
partum follow-up screening for diabetes in women with
GDM via the 2-hr 75-gram OGTT at 6-9 weeks postpar-
tum as recommended by the ADA [66]. As part of this
SWIFT study, we conduct the follow-up OGTT during
the baseline study visit, perform in-person interviews,
and obtain anthropometric measurements during the 2 h
period. Women who are free of diabetes at the baseline
visit are screened for incident diabetes annually for 2
years, and undergo assessments of other parameters.
The National Institutes of Health provided funding to
conduct the study (5-years from the National Institute
of Child Health and Human Development, R01
HD050625). The study protocol was approved by the
Institutional Review Board at Kaiser Permanente North-
ern California.
Study sample
Study cohort
The cohort is being recruited from 13 KPNC medical
centers and medical office facilities through the 5, 000
square mile KPNC region. Participating sites within the
three areas include: North area: Sacramento, South
Sacramento, and Roseville Medical Centers, and Rancho
Cordova, Elk Grove, Point West, and Folsom Medical
Offices; East area: Division of Research (DOR) Research
Clinic (Oakland), Hayward and Richmond Medical Cen-
ter; South area: Fremont, Santa Clara, and San Jose
Medical Centers. The cohort includes women who
received prenatal care and delivered a singleton, live
born infant at a KPNC hospital between July 2008 and
October 2011.
Eligibility criteria
Age 20-45 years at delivery,
Availability of clinical medical record and delivery
record from the KPNC Health Connect electronic medi-
cal record,
GDM pregnancy diagnosed by Carpenter and Cou-
stan’s criteria,
Delivered a singleton, live birth ≥ 35 weeks gestation,
No pre-existing diabetes or other serious medical con-
ditions prior to index GDM pregnancy,
No diabetes diagnosis at 6-9 weeks postpartum for the
index GDM pregnancy,
No use of steroids, or other medications significantly
affecting glucose tolerance,
Not planning to move from the northern California
area within the subsequent 2 years,
Not planning another pregnancy within the next 2
years, and
English or Spanish speaking.
Eligibility is also based on infant feeding practices,
infant feeding intentions and status at 6-9 weeks
postpartum:
Intensive formula feeding: did not breastfed or pro-
vided at least 14 oz of formula per day during the first 4
months postpartum.
Intensive lactation: only breast milk or no more than 6
oz/day of formula supplementation within 6-9 weeks
postpartum, and intention to continue breastfeeding
intensively for at least 4 months postpartum.
Sample size and power calculation
The target recruitment sample is 1, 098 women with
recent GDM who are free of type 2 diabetes at 6-9
weeks postpartum, with the expectation of having them
equally distributed into the two infant feeding groups (i.
e. intensive formula feeding, and intensive lactation
groups).
Based on a previous study of pregnant women at
KPNC [67] and on KPNC clinical data, we expect 89.8%
of the sample to remain in analyses of the 1-year exam
(N = 986), and 78.5% to remain in analyses of the 2-
year exam (N = 862).
For assessing Aim 1, assuming a two-year postpartum
cumulative incidence of type 2 diabetes of approximately
20% as described in our KPNC GDM population [68],
and given the expected censoring rates above, we expect
to observe approximately 172 incident cases of type 2
diabetes. We will have sufficient power (0.80) to detect
a relative hazard of type 2 diabetes associated with
intensive lactation of 0.65 (Table 1).
We also estimated minimum detectable absolute dif-
ferences in mean change from baseline in a continuous
variable, expressed in standard deviation units, at the
year 1 and year 2 exams (relevant to Aim 2 and 3).
Based on published estimates [39,56] of standard devia-
tions of 1 year change, we will have sufficient power to
detect the following mean changes in the outcomes
across infant feeding categories at year 1: plasma glucose
and insulin, respectively, 0.45 mg/dl and 0.27 μU/ml at
fasting, and 1.69 mg/dl and 3.38 μU/ml at 2-hr post
load, and postpartum weight 0.25 kg and waist girth
0.28 cm.
To test Aim 4, we assumed a graded linear trend in
relative hazards across quartiles of adiposity and plasma
adiponectin measures. Power calculations are conserva-
tively based on a global test for association by treating
the risk factor as a categorical variable in the Cox model
(i.e., testing a set of indicator variables rather than a test
for linear trend) (Table 2).
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with adjustment for multiple confounding, we calculated
minimum detectable additional (or incremental) propor-
tions of variance in the dependent variable explained by
infant feeding practices (denoted ΔR
2) over and above
that already explained by a given set of confounders
(denoted R
2). Assuming a range in R
2 of 0.05 -0.30, a
power of 0.80 and a 10-parameter model, minimum
detectable incremental variance in outcome explained
by infant feeding practices (intensive lactation vs. inten-
sive formula feeding) ranges from 0.55% to 0.75%,
depending on the explanatory power of confounding
variables included in the model (Table 3; calculations
presented are for the one-year visit).
Study procedures
Eligibility screening and data collection activities for this
longitudinal cohort study include three telephone con-
tacts, three in-person study visits and 10 mailing con-
tacts from late pregnancy through 2 years postpartum
(Figure 2). Recruitment is expected to be completed in
December 2011.
Eligibility pre-screening activities
Once a week a list of women recently diagnosed with
GDM in one of the 13 study sites is populated into a
Tracking System (TS) specially created for the study.
Authorized study staff reviews the electronic medical
records of the women listed to verify language prefer-
ence, eligibility information, if available (i.e. singleton vs.
multiple pregnancy and estimated delivery date), and
primary KPNC clinical care provider’s name.
KP providers are contacted via email to request
authorization to contact their patients. Passive approval
is assumed after 2 weeks as explained in the email letter.
An invitation letter describing the study is sent to
potential participants along with a pre-paid postage,
addressed refusal return card to indicate whether they
want or not to be contacted by the study staff and the
best way to be reached.
Around 33 weeks of gestation, study staff call potential
participants to describe the study and administer a pre-
screening questionnaire asking about moving, pregnancy
and infant feeding plans using a standardized scale
[69,70], as well as other eligibility criteria (e.g. pre-exist-
ing diabetes, singleton vs. multiple gestation).
Screening phone call
Once a week the TS is populated with delivery informa-
tion (i.e. singleton, live birth > = 35 weeks of gestation,
birth weight and length and Apgar score) from KPNC
electronic medical databases for potential participants
who gave birth, which allows to confirm eligibility for
further contacts.
Around 2-4 weeks postpartum, potential participants
are contacted by phone to determine their interest and
eligibility to participate in the study. At the telephone
screening contact, a screening questionnaire similar to
the one administered during late pregnancy is com-
pleted; additionally, infant feeding practices are assessed
to determine potential eligibility as described below. Eli-
gible women are invited to participate in the study and
scheduled for their baseline study visit at 6-9 weeks
postpartum.
Study visits
Study data collection occurring at in-person visits to
KPNC clinics is scheduled at the following postpartum
time points: Visit 1 at 6-9 weeks (baseline), Visit 2 at 12
Table 1 Minimum detectable relative hazard of incident Type 2 diabetes mellitus and minimum detectable differences
in mean change in biochemical measures
a
Outcomes Relative Hazard; 2-year Cumulative
probability of Incident Type 2 DM = .20
Detectable Difference (SD units) in
Mean change 1-year, N1 =N 2 = 493
Detectable Difference (SD Units) in
Mean change 2-year, N1 =N 2 = 431
Infant
Feeding
Categories
Intensive
formula
feeding
(referent) (referent) (referent)
Intensive
lactation
(4 or more
months)
0.65 0.179 0.191
a Standard deviation units, two-sided test, significance level = 0.05, power = 0.80.
Table 2 Minimum detectable relative hazards of Incident
Type 2 Diabetes Mellitus associated with quartiles of
adiposity and adiponectin
a
Quartiles Relative Hazard (> 1;
adiposity)
Relative Hazard (< 1;
adiponectin)
Q1 (referent) (referent)
Q2 1.26 0.79
Q3 1.58 0.63
Q4 1.98 0.50
aTwo-sided test, significance level = 0.05, power = 0.80
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Page 7 of 15months and Visit 3 at 24 months postpartum. The study
visits take place at the 13 KPNC clinical facilities where
we are approved to implement the study protocol and
conduct visits.
Signed informed consent for participating in the study
is obtained at the baseline in-person visit which includes
permission to obtain information on perinatal outcomes
from electronic databases.
Study procedures at each visit include anthropometric
measurements, self- and interviewer-administered ques-
tionnaires to collect data on socio-demographics, clinical
(reproductive and medical history, depression), and early
postpartum behavioral characteristics (infant feeding
practices, smoking and alcohol consumption, dietary
and caffeine intake, physical activity and sleeping pat-
terns), and administration of the 2-hour, 75-gram
OGTT and collection of blood specimens (fasting and
post load). Diagnosis of diabet e sr e q u i r e sc o n f i r m a t i o n
by a second laboratory test on another day. Women
who are free of type 2 diabetes at baseline are followed
prospectively, while women who are confirmed with dia-
betes are informed via a study letter and recommended
to contact their health care provider for treatment and
education.
Table 3 Minimum detectable increases in the proportion of variance in continuous variables explained by infant
feeding
a, b, c
Variable tested Degrees of Freedom for Test Variable R
2 for confounders
0.05 0.10 0.20 0.30
Infant feeding (intensive lactation vs. intensive formula feeding) 1 0.0075 0.0071 0.0063 0.0055
aContinuous variables: plasma glucose and insulin levels, indices of insulin secretion, body weight or waist girth, and adiponectin
bAdjusting for confounders that account for various proportions of explained variance (R
2)
cN = 986 (one-year exam), significance level = 0.05, power = 0.80
Timeline: 
     Pregnancy                                           Postpartum 
contacts (P):                          P1                   P2                    P3  
  pregnancy 
screening 
33wk 
  Delivery      Enrollment          
 
postpartum 
screening 
2-4wk 
contacts:          Invitation Letter                                 Monthly Questionnaires                
visits:                                                                Visit 1                             Visit 2                                                Visit 3 
                                                                   6-10 wk postpartum          1yr postpartum                                  2 yr postpartum      
postpartum 
follow-up 
  6mo 
    31 wk of gestation 
3mo 
postpartum 
11mo 
postpartum 
Telephone 
Mailing 
 & Card  
In-person 
Legend 
Telephone contacts (P) 
Mailing contacts  
In-person visits  
Figure 2 Schedule of study contacts and assessments.
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Page 8 of 15Spanish versions of the consent form and each ques-
tionnaire are available for participants whose preferred
language is Spanish.
Mailing questionnaires
After the baseline study visit, participants begin receiv-
ing a monthly mailing questionnaire with a pre-paid
postage, addressed return envelope (non-respondents
are contacted by phone) from 3 through 11 months
postpartum which assesses lactation status and use of
milk supplements and other infant foods during the pre-
vious week. Additional questions about contraceptive
use, pregnancy status and recent diabetes diagnosis are
also included in the questionnaire.
Phone follow-up interview
At 6 months postpartum, a 20-minute follow-up phone
interview is conducted to collect data on maternal and
child health (e.g. health problems, medications, recent dia-
betes diagnostic), pregnancy status and contraceptive use,
socio-demographic information (school attendance and
maternal employment status) and infant feeding history.
A subset of women and their children are enrolled in
an ancillary study (SWIFT Offspring Study) which
involves attending a study visit at 6 months postpartum;
for those women the option to complete the six-month
questionnaire at that visit (instead of doing it over the
phone) is offered.
Assessment of the main exposure of the study
Lactation intention assessed in late pregnancy
We assess lactation intentions using the Infant Feeding
Intentions (IFI) scale developed by Nommsen-Rivers
and Dewey [69] to quantitatively measure maternal
breastfeeding intentions. The first 2 items of the scale
measure strength of intentions to initiate breastfeeding
and subsequent items assess strength of intentions to be
breastfeeding exclusively at 1, 3 or 6 months. The IFI
scale provides total scores ranging from 0 ot 16; it has
demonstrated strong internal consistency, content and
construct validity [69], and it has been used successfully
with diverse populations [70].
Formula feeding log mailed at 2 weeks postpartum
A formula feeding log is mailed to mothers 2 weeks
after delivery on which they are asked to record the
amount of infant formula given per bottle and the aver-
age number of bottles given at each week postpartum,
since birth through week 5. This log is an aid for
answering the questions on infant feeding asked by
phone at 4 weeks postpartum.
Lactation status and intention assessed at the 4-week
postpartum telephone call
Potential participants are asked about their infant feed-
ing practices to determine their eligibility. Data collected
include information on breastfeeding (ever and current),
breast milk expression and weaning. In addition, they
are asked about infant formula use, including starting
date, number of days that formula was given to the baby
and the average amount given per day, both since birth
and during the past week. Data on introduction of any
other liquids and the amount given are also collected.
Intentions to continue breastfeeding until at least 3 or 6
months are explored using two items from the IFI
among those who are either giving breast milk only or
no more than 6 oz of formula per day. Based on their
responses, mixed feeding mothers (50% breast milk and
50% formula) are identified, considered ineligible for the
study and therefore not invited to enroll.
Lactation status at enrollment (baseline) and follow up
visits
At the baseline visit, participants complete an inter-
viewer-administered questionnaire on breastfeeding.
Questions include time of milk arrival (lactogenesis
stage II), usual breastfeeding frequency during the day
and night, typical frequency of breast milk expression
and of expressed-breast-milk feeding, weaning date and
reasons for not initiating breastfeeding or weaning are
also asked.
In addition, mothers are asked about introduction of
infant formula or other milk, date it started, kind of for-
mula/milk, usual number of bottles given per day and
typical number of ounces the baby drank from the bot-
tle. Similarly, introduction of sweetened water, fruit
juice and other liquids is also asked, as well as use of
Pedialyte, a common treatment for diarrhea. We also
ask them about introduction of any solid foods, starting
date, type and average given per day during the past
week. Finally, mothers are asked about their reasons for
introducing formula.
Similar information about lactation is collected at the
follow up visits when the child is about 1 and 2 years of
age. Additionally, information on lactation history (i.e.
breastfeeding duration per each older child and mater-
nal age at first and last lactation) is collected at the last
in-person visit (visit 3).
Lactation assessment from 3 through 11 months
postpartum
A monthly assessment of lactation status, use of milk
supplements and other infant foods during the previous
week is done using mailing questionnaires. We ask
about baby’s age at weaning, breastfeeding frequency
(during the day and night), and breast milk expression
frequency, age at first formula feeding, formula feeding
frequency and ounces per bottle, introduction of any
other liquids or solid foods, and age when first given.
At 6 months postpartum, participants are interviewed
over the phone to collect similar information on infant
feeding practices.
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Diagnosis of type 2 diabetes
Diagnosis of incident type 2 diabetes is the primary out-
come of the SWIFT study and is defined according to
the 1997 ADA criteria [71]: fasting plasma glucose
( F P G )>=1 2 6m g / d Lo r2 - h o u rp l a s m ag l u c o s e( 2 - h
PG) after a 75-gram oral glucose load > = 200 mg/dL.
The diagnosis will require confirmation by a second test
according to the same criteria [71]. We determine dia-
betes status using data obtained from OGTT at 6-9
weeks, 12 months, and 24 months postpartum in all
participants.
For women who will have diabetes diagnosed by their
physician at follow-up visits, their medical record will be
reviewed in order to assess diagnostic plasma glucose
values and they will have fasting plasma glucose tested
in order to confirm diabetes status according to the
study criteria [71].
Insulin resistance
Indices of insulin resistance will include the insulin sen-
sitivity index (ISI), quantitative insulin sensitivity check
index (QUICKI) and homeostatic method (HOMA-IR)
based on glucose and insulin measures. HOMA-IR and
QUICKI are strongly correlated (0.6-0.8) with euglyce-
mic-hyperinsulinemic clamp and FSIGT techniques
which are the most accurate, direct measures of insulin
resistance. We will assess insulin resistance and sensitiv-
ity using data obtained from 0 to 120 min during
OGTT at 6-9 weeks, 12 months, and 24 months post-
partum in the cohort.
Body size and central adiposity measurements
Weight and waist circumference will be measured at
baseline and each follow-up visit, and height will be
measured at baseline. BMI will be calculated as weight
(kg) divided by height (m) squared and used to evaluate
overweight/obesity or total adiposity. Central adiposity
will be assessed by waist girth.
Other study measurements
Anthropometry
Weight and waist circumference are measured at baseline
and each follow-up visit. Women are weighed at 12 sites
using a portable Tanita WB 100A digital scale, which
measures up to 440 lb (or 200 kg). At the 13th site (DOR
Research Clinic) we obtain weight using a Tanita Model
3101 Portable Medical Stand-On scale which measures
up to 900 lb. Women are measured in light clothing (e.g.
no jacket or sweater) and without shoes, after emptying
their pockets and removing any accessories that could
impact their weight measurement (e.g. cell phones, jew-
elry, watches or belts). Weight measurements are
recorded in pounds with 0.2 lb graduation.
Waist circumference is measured in centimeters to the
nearest millimeter using the Gulick II Plus anthropometric
tape (Model 67019). This no-stretch, retractable tape with
both centimeter and inch gradations, has a tensioning
device attached to provide a known amount of tension
while a measurement is being taken. Unless the participant
refuses, the tape is applied directly on the skin, horizon-
tally at a level laterally that is midway between the iliac
crest and the lowest lateral portion of the rib cage and
anteriorly midway between the xiphoid process of the ster-
num and the umbilicus. Two consecutive measurements
are taken and recorded, and a third measurement is taken
and recorded if the first and second measurements differ
more than 1 cm.
Height is measured only at baseline, using a Seca Por-
table Stadiometer (Model 67029) with a measurement
range between 8” and 82” a n dg r a d a t i o n si ni n c h e sa n d
centimeters. Height measurements are recorded in cen-
timeters to the nearest millimeter. Participants are asked
to remove their shoes and any hair ornaments to get an
accurate measurement.
Dietary intake
The PrimeScreen [72], a brief self-administered food fre-
quency questionnaire, is being used to assess quality of
participants’ diet. This dietary tool has demonstrated
adequate reproducibility when re-administered after 2
weeks, and its results compared well with two reference
standards: the self-administered brief semi-quantitative
food frequency questionnaire (SSFQ) by Willet and col-
leagues [73] and plasma levels of selected nutrients [72].
It consists of 18 questions about average frequency of
consumption of specified foods and food groups, and
another 7 items about vitamin and supplement intake.
The original recall timeframe was the past year; how-
e v e r ,f o rt h ep u r p o s eo ft h i ss t u d yw eu s e dap a s tw e e k
recall timeframe. The five frequency of consumption
categories used are: none (we changed the original ‘less
than once per week’ category to make it consistent with
the modified recall timeframe), once (originally ‘once
per week’), 2-4 times (originally ‘2-4 times per week’),
nearly daily or daily, or twice or more per day.
In this study we use the PrimeScreen as an inter-
viewer-administered questionnaire. Cue cards displaying
the answer options or pictures of several food items
were prepared as supplemental materials. These aids are
particularly helpful for interviews in Spanish, given that
some foods have different names in different dialects.
Caffeine intake
The Supplemental Beverage Questions (
© 2004 Fred
Hutchinson Cancer Research Center) was selected to
assess caffeine intake. The questionnaire, which is avail-
able to the public at the center’s web page, ask about
the frequency of consumption of 13 groups of caffei-
nated and non-caffeinated beverages, as well as the ser-
ving size in relation to what is considered a medium
serving size (i.e. an 8-ounce cup for coffee or tea, a shot
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original questionnaire, available on-line, does not indi-
cate a specific recall timeframe; for the purpose of this
study, we asked about caffeine intake during the past
month.
Physical activity
Physical activity is assessed at each study visit using an
adapted version of the Pregnancy Physical Activity
Questionnaire (PPAQ) developed by Chasan-Taber and
colleagues [74]. The PPAQ is a self-administered semi-
quantitative questionnaire that asks respondents to
report the time spent participating in 32 activities
including household/caregiving (13 activities), occupa-
tional (5 activities), sports/exercise (8 activities), trans-
portation (3 activities), and inactivity (3 activities). For
each activity, respondents are asked to select the dura-
tion category that best approximates the amount of time
spent in that activity per day or week during the current
trimester of pregnancy. Duration categories range from
0 to 3 or more hours per day or week, except for occu-
pational activities with a range from 0 to 6 or more
hours per day. The PPAQ has been validated with preg-
nant women with reproducibility measures from 0.78 to
0.93 depending on the type of activity [74].
The PPAQ was selected under the assumption that
postpartum women have similar physical activity patters
as pregnant women, but we slightly adapted it for use
with non-pregnant women. The recall timeframe was
changed to the past week, an item on prenatal exercise
class was modified to ‘postnatal’ exercise class (for the
baseline visit) and to ‘exercise class’ (including space to
specify which kind, for the follow-up visits), and an
activity expected among women with young children
was added as an item (i.e. ‘walking, pushing a stroller’).
In addition, two other items were modified: a) we added
‘walking a dog’ to the ‘playing with pets’ item, and b) we
deleted the word ‘quickly’ from the ‘walking quickly up
hills for fun or exercise’ item. For this study, the ques-
tionnaire was interviewer-administered.
Sleep questionnaire
T h eS l e e pQ u e s t i o n n a i r eh a stwo sections: a) general
sleep habits and b) the general sleep disturbance scale
(GSDS) adapted from a sleep questionnaire for the post-
partum period [75]. The General Sleep Habits section
was developed for the study and consisted of 6 ques-
tions regarding sleep habits during the past week. Infor-
mation asked includes: get-up and go-to-bed time, time
to fall sleep, frequency of waking up in the night, hours
of actual sleep at night, minutes of actual sleep from
naps. Questions about get up/go to bed time and min-
utes/hours of actual sleep are asked both, for week days
(or work days) and for the weekend (or days off).
The GSDS is used to assess subjective sleep character-
istics during the past 7 days. The GSDS is a 21-item,
0-7 rating scale, which includes seven subscales: sleep
onset, waking up during sleep, waking up too early from
sleep, quality of sleep, quantity of sleep, daytime func-
tioning, and use of substances to help induce sleep [75].
Higher scores indicate more disturbed sleep, and a
mean score of 3 on the total GSDS or any of the sub-
scales represents the ‘3 days per week’ DSM-IV criterion
for insomnia, which is considered a clinically significant
sleep disturbance [75]. The GSDS has been successfully
used with postpartum mothers [76,77].
Depression
The 20-item Center for Epidemiologic Studies-Depres-
sion (CES-D) [78] is used to assess depression symp-
toms over the past 7 days. The CES-D has been broadly
used in epidemiologic research with different racial and
ethnic populations in the United States, showing similar
reliability and general structure of responses among
these groups [79]. This scale is widely used with preg-
nant and postpartum women populations and provides
a consistent assessment at the longitudinal visits [80-82].
A score of 16 indicates high risk for clinical depression
[78].
Clinical risk factors
Using self- and interviewer-administered questionnaires,
we collect information on clinical risk factors at the in-
person visits. We ask about family history of diabetes,
previous pregnancy GDM diagnosis and other perinatal
complications, pre-pregnancy weight, current medical
conditions, medication use, pregnancy status after
enrollment (intercurrent pregnancies), and hormonal
contraceptive use, including type and duration.
Women who develop medical conditions during the
study period may continue their participation, except for
rare diagnoses of cancer (except for skin cancer), major
organ failure (kidney, heart, or liver) or other life-threa-
tening conditions. Women who become pregnant during
follow up continue in the study after the delivery of the
additional pregnancy. Electronic databases will be used
to confirm some of this information.
Biospecimen procedures and laboratory assays
Venous blood is drawn from participants in a non-preg-
nant state by a trained phlebotomist at each study visit.
A fasting blood sample is drawn after a minimum of 8 h
of overnight fasting, followed by consumption of the 75-
gram oral glucose solution (within a period of 5 min),
and followed by a second blood sample 2 h after the
intake of the glucola beverage. Participants are
instructed not to smoke, walk or engage in any physical
activity, not to chew gum, eat mints or candy, and not
to consume any food or beverages during the test,
except small sips (3 oz) of plain water. Normally, the
participants complete all the other study assessments
(i.e. anthropometric measurements and questionnaires)
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are instructed to breastfeed their babies and/or express
breast milk before the fasting blood sample is drawn,
and the frequency and duration of any breastfeeding
during the test is recorded. At every visit, 30 mL of
blood are drawn into ethylene diamine tetraacetic acid
(EDTA) tubes for the fasting blood draw, and 15 mL of
blood are drawn for the 2-hour post glucola blood draw
for measurement of glucose and insulin.
Blood samples are processed, aliquoted and placed in
the freezer within 90 min of collection. Using the internal
KP courier system for biospecimens, aliquoted plasma is
then transported from the study sites to the KPNC
Regional Laboratory and from there to the DOR research
clinic for storage at -70°C, in a low temperature freezer
maintained and monitored at constant temperature.
Upon arrival at the DOR research clinic, cryogenic vials
are scanned into the SWIFT biospecimens database.
Stored samples for analyses are shipped monthly to the
University of Washington, Northwest Lipid Research
Laboratories, Immunoassay Core of the Diabetes Endo-
crinology Research Center (DE R C )a tt h eU n i v e r s i t yo f
Washington, Seattle, Washington (Dr. Santica Marcov-
ina, Director) for analysis of glucose, and insulin.
Analyses of glucose are performed enzymatically on
Hitachi 917 Autoanalyzer using the combined catalytic
activities of hexokinase and glucose-6-phosphate-dehy-
drogenase. The assay of total immunoreactive insulin, or
total insulin, is performed by a double-antibody radio-
immunoassay developed in the Diabetes Endocrinology
Research Center Immunoassay Core Laboratory.
Retrieval of data from KP electronic databases and
medical records
Some data will be collected using electronic databases to
obtain accurate information and decrease the study time
burden on subjects. Pregnancy outcomes data are avail-
able in KPNC in-patient and outpatient databases
including labor and delivery history, infant birth weight
and length, Apgar scores, neonatal intensive care unit
admissions, formula intake, medical history, gestational
age at diagnosis of GDM, 100-g, 3-hour OGTT results,
insulin use during pregnancy, mode of delivery, preg-
nancy admissions, treatments and complications. Mea-
sured gestational weights, information on subsequent
(inter-current) pregnancies and other pregnancy compli-
cations can also be obtained or confirmed from those
electronic databases. Data on hormonal contraceptives
during the postpartum period are also available from
the pharmacy electronic databases.
Quality control procedures
Detailed manuals were developed describing data collec-
tion procedures. Research staff completes training led by
the Project Manager which includes a series of sha-
dowed study activities with each data collector before
this person can start performing any study activity and
observation when they conduct their first few measure-
ments with actual participants. Initial training for
anthropometric measurements involved measuring 5
female adult volunteers following a standard protocol
and comparing measurements by the technicians with
those of the Project Manager, who had training in nutri-
tion and was considered the gold standard. Throughout
the study, refresher trainings involving all data collectors
are being conducted twice per year.
A relational database architecture (TS) has been devel-
oped in “Access” specifically for this study. The TS was
designed to be populated weekly with potential partici-
pants (women recently diagnosed with GDM), to evaluate
study eligibility, to track participants and to enter study
data. It includes all data from prenatal and delivery
record abstraction, blood analyses, participant appoint-
ments, contact and provider information, screening inter-
views, study questionnaires and results from any contact
with participants or potential participants. Data from the
questionnaires are entered by study staff into the TS and
transferred to SAS data sets for data cleaning, merging,
analysis and reporting. All data are secured from external
access through password protection and tracking of
access to accounts on the central mainframe, and PC
workstations, and from computer equipment failure by
daily incremental back-up and off-site archival.
Different strategies are in place to increase participa-
tion and retention. The annual OGTT testing for type 2
diabetes is not routinely done at KPNC and is presented
as a good reason to participate. The study provides par-
ticipants with a copy of their OGTT results to give to
their primary care provider. Women are allowed to
bring their infants to the study visits, and are given a
light breakfast after the 2-hour blood draw. Incentives
for participating include: 1) a $60 gift card for attending
and completing a study visit, 2) a waiver of any co-pay
for the OGTT performed at each study visit, 3) parking
validation for attending a study visit, if applicable, 4)
additional small gifts for attendance to each visit, such
as bibs, 5) a $15 gift card for completing and returning
6 (out of 9) monthly mailed questionnaires during the
first year of participation.
Retention is maximized by mailings of reminder letters
to all participants scheduled for a study visit; text mes-
sages and/or emails are sent before each study visit. In
addition, contact information is confirmed at any in-per-
son, phone or mail contact.
Discussion
SWIFT is the first study to prospectively examine
whether lactation intensity and duration are associated
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after GDM pregnancy, controlling for multiple potential
confounders. However, as an observational study, it has
some specific limitations. Because women are not ran-
domly assigned to infant feeding groups there is a
chance for unequal distribution of confounders among
the exposure groups and inherent differences due to
their selection of the specific behavior. To address this
potential for bias, we measure as many as possible
known potential confounders (i.e., lifestyle behaviors),
and adjust for pertinent ones in the analysis. We plan to
analyze our results controlling for potential confounding
from clinical and postpartum behavioral and clinical risk
factors that have not been assessed in previous studies.
Another limitation relates to the indices of insulin
resistance, HOMA-IR and QUICKI, which are not as
accurate as the euglycemic-hyperinsulinemic clamp or
FSIGT to measure insulin sensitivity/resistance. The
indices of insulin resistance have been widely used in
population-based studies and are good predictors of
future diabetes. The clamp and FSIGT methods are not
feasible for large epidemiologic studies, especially with
repeated measurements because the technique is time
consuming, invasive and expensive. Postpartum women
without any overt disease are unlikely to participate in
such invasive procedures.
A particular advantage of SWIFT relates to its popula-
tion within the KPNC integrated healthcare system set-
ting. The racial/ethnic diversity of the KPNC population
increases our chances to obtain a representative sample
and permit generalizability of the findings; also the high
retention observed (> 80%) in previous KPNC studies is
an important goal in cohort studies. Furthermore, the
accessibility of patient’s data from the KPNC electronic
medical records will lessen subject burden and allow for
confirmation of self-reported data.
Moreover, the SWIFT study will be able to evaluate
short-term effects of lactation on maternal glucose
homeostasis and adiposity which will provide data on
possible mechanism to explain any association between
lactation and incidence of type 2 diabetes during the fol-
low-up period.
If lactation is found to have persistent effects on
maternal glucose homeostasis that prevent type 2 dia-
betes in women, then translation of the findings from
the SWIFT may have a significant public health impact.
Lactation promotion would be a low-cost, feasible strat-
egy that may enhance postpartum behavioral interven-
tions for the prevention of diabetes in women.
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